Understanding competing risks: a simulation point of view
about
How to handle mortality when investigating length of hospital stay and time to clinical stabilitySimulating recurrent event data with hazard functions defined on a total time scale.Multistate Models on Pleural Effusion after Allogeneic Hematopoietic Stem Cell TransplantationAge and decisions to limit life support for patients with acute lung injury: a prospective cohort study.Empirical comparison of methods for analyzing multiple time-to-event outcomes in a non-inferiority trial: a breast cancer study.Estimation of the standardized risk difference and ratio in a competing risks framework: application to injection drug use and progression to AIDS after initiation of antiretroviral therapyTesting the treatment effect on competing causes of death in oncology clinical trialsCompetitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD.Effect of diabetes mellitus on giant cell arteritis.The importance of distinguishing between the odds ratio and the incidence rate ratio in GWAS.The use and interpretation of competing risks regression modelsThe Effect of a Multi-Level Intervention on the Initiation of Antiretroviral Therapy (ART) among HIV-Infected Men Who Inject Drugs and Were Diagnosed Late in Thai Nguyen, Vietnam.Treatment intensification using long-acting insulin -predictors of future basal insulin supported oral therapy in the DIVE registryEvaluating hospital performance based on excess cause-specific incidenceCumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study.Modeling and prediction of subject accrual and event times in clinical trials: a systematic review.Applying competing risks regression models: an overview.Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death.Modelling two cause-specific hazards of competing risks in one cumulative proportional odds model?The time-dependent "cure-death" model investigating two equally important endpoints simultaneously in trials treating high-risk patients with resistant pathogens.Vaginal native tissue repair versus transvaginal mesh repair for apical prolapse: how utilizing different methods of analysis affects the estimated trade-off between reoperation for mesh exposure/erosion and reoperation for recurrent prolapse.Methodologic Issues When Estimating Risks in Pharmacoepidemiology.Effect of alcohol consumption on all-cause and liver-related mortality among HIV-infected individuals.Bias Due to Confounders for the Exposure-Competing Risk Relationship.Dementia onset, incidence and risk in type 2 diabetes: a matched cohort study with the Fremantle Diabetes Study Phase I.Association of injection drug use with incidence of HIV-associated non-AIDS-related morbidity by age, 1995-2014.Estimating sample size in the presence of competing risks - Cause-specific hazard or cumulative incidence approach?When to Censor?Testing Mean Differences among Groups: Multivariate and Repeated Measures Analysis with Minimal Assumptions.Missingness in the Setting of Competing Risks: from missing values to missing potential outcomesAssociation between Obesity and Cancer: An Analysis Using the Competing Risk Regression Approach
P2860
Q23913313-368D22DE-B547-4DDB-8DB1-63042CA68B2CQ30935524-FC5DDBFC-7C4A-47C5-BEE3-8AB83293D6C0Q33573710-D8E866DF-BAC7-4EF4-AB76-607E59879F06Q33822003-DF6ABCA0-42C2-4A0F-96E5-082C2C2767EDQ34630887-DA8607D9-8681-4853-8370-8A43B7672784Q35076584-B7D74A7C-F3C4-4D8C-9E7D-8CEACE57DDA5Q35177617-1BEB8F4C-E335-44CE-B8F1-FC7E60332D79Q35228536-EB9CC893-FC18-42B0-A678-29E6557B294FQ35688053-6638C14E-D1B5-4821-8F96-10A41C6E00C5Q35759568-32C4AF17-0DAC-4378-8581-00A59536709CQ35894830-CC184A6F-AACC-4378-84A6-BFBADE88410DQ36118406-981B3EED-D712-4F0B-81E3-64444047F9AFQ36134920-EE6DDAC0-49CC-4E24-8B5E-A5260067D265Q36311241-11F4E614-2ECD-44C2-A86D-E933AD7BB08DQ36459660-449127EB-2525-42C3-B260-6A4C01085018Q38016816-9BE08E70-4F25-4656-8E3A-AF6B02C2C8F9Q38046436-89E552F0-1306-4EF6-83B1-27544CFCEA42Q38392698-6AAC857D-71D0-44FF-AD60-E7E8A5186DECQ38612146-EE0F1DE9-0BCF-4B6B-A0D6-CDF64A803376Q38672879-9D987AA4-1BB3-4174-8438-47831AF39309Q39044181-8BB4FC40-B09F-472D-8867-DDDDA1F5A3D8Q40077021-CFF0066E-AD2A-4B08-B1C8-277FB91B1015Q40525196-75807651-9115-49EE-BBC7-C54A3224A750Q40538737-F7FBFFB7-371B-4243-A3EB-B211ABF31591Q40549777-FAC54D8B-99C0-4F6C-B0C4-A271C410855DQ40750446-7BA6F1DE-1B12-4397-97A7-204B6188A153Q47337078-C1BE2FC0-3154-4EE5-B591-8A24E241FD90Q50094102-541EF89C-5A59-4742-A545-95E5ECAE7CD0Q54962260-566A872E-DDDA-48E6-B8F3-0D6F9D0E04E1Q58573006-93A6CA6B-3027-43DE-85E4-4BE1A97A00F4Q59103155-DF582E52-1B02-4074-BD5C-468F0AB7712B
P2860
Understanding competing risks: a simulation point of view
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Understanding competing risks: a simulation point of view
@ast
Understanding competing risks: a simulation point of view
@en
type
label
Understanding competing risks: a simulation point of view
@ast
Understanding competing risks: a simulation point of view
@en
prefLabel
Understanding competing risks: a simulation point of view
@ast
Understanding competing risks: a simulation point of view
@en
P2093
P2860
P356
P1476
Understanding competing risks: a simulation point of view
@en
P2093
Arthur Allignol
Christiane Drechsler
Christoph Wanner
Jan Beyersmann
Martin Schumacher
P2860
P2888
P356
10.1186/1471-2288-11-86
P577
2011-06-03T00:00:00Z
P5875
P6179
1022186975